Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20971487 | 0.86 | FGFR4 (0.65) | FGFR4 | |
| SCHEMBL18095771 | 0.83 | FGFR4 (0.61) | FGFR4 | |
| SCHEMBL20971477 | 0.79 | FGFR4 (1.00) | FGFR4 | |
| SCHEMBL18095761 | 0.79 | FGFR4 (0.63) | FGFR4 | |
| SCHEMBL18095728 | 0.78 | FGFR4 (0.62) | FGFR4 | |
| SCHEMBL28580700 | 0.77 | FGFR4 (0.55) | FGFR4 | |
| SCHEMBL16671048 | 0.74 | FGFR4 (0.55) | FGFR4 | |
| SCHEMBL16667895 | 0.74 | FGFR4 (0.74) | FGFR4 | |
| SCHEMBL18095688 | 0.74 | FGFR4 (0.75) | FGFR4 | |
| SCHEMBL18095721 | 0.74 | FGFR4 (0.61) | FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180065951-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS PHARMA AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-20180065951-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS PHARMA AG (CH) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065951-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | FGFR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.